• Publications
  • Influence
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
A multidisciplinary, international group of experts discussed the current status and future directions of MCI, with regard to clinical presentation, cognitive and functional assessment, and the role of neuroimaging, biomarkers and genetics. Expand
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease
This research framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms and envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD. Expand
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
It is proposed that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. Expand
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects.
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
The association between pathological CSF and progression to Alzheimer's disease was much stronger than, and independent of, established risk factors including age, sex, education, APOE genotype, and plasma homocysteine. Expand
CSF markers for incipient Alzheimer's disease
The CSF biomarkers total tau protein, phosphorylated tauprotein, and the 42 amino-acid residue form of amyloid-beta may, if put in the right clinical context, prove to have high enough diagnostic accuracy to meet the challenge of identifying incipient AD in patients with MCI. Expand
Alzheimer's disease
This seminar reviews the key aspects of the disease, including epidemiology, genetics, pathogenesis, diagnosis, and treatment, as well as recent developments and controversies. Expand
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
The rationales behind and the diagnostic performances of the core cerebrospinal fluid biomarkers for AD, namely total tau, phosphorylated tau and the 42 amino acid form of amyloid-β are presented. Expand
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Biological analysis of the 18 proteins found in blood plasma points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease. Expand
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. Expand